welcome letter

call for abstracts
Details and submission on www.pamm2015.com
Deadline: November 15, 2014
welcome letter
The 36th PAMM-EORTC Winter Meeting will focus on ground-
breaking innovations in experimental and clinical oncology.
The PAMM (Pharmacology And Molecular Mechanism) Meeting
is organized under the umbrella of European Organization for Treatment
of Cancer (EORTC), to provide a unique opportunity for interdisciplinary
You are much welcome to submit materials for consideration by the PAMM-2015
Program Committee. Both PAMM and non-PAMM members are allowed to submit
abstracts. Ph.D. students and Post-Doc fellows can submit materials for the Young
Researcher session.
Abstracts should be prepared as following:
- An English language abstract must be in the terminology familiar to specialists.
-The text should be succinct and substantive.Beside presenter’s full names and affiliations,
the abstract must include: Purpose, Methods, Results, Conclusion, and Significance. - Submit a Microsoft Word document no longer than 750 words or one-page in length.
-Ifyou would like to include an image(s),be sure to embed the image(s) in the Word document.
Please specify whether you want your abstract to be considered for:
- Plenary session (oral presentation - 22-23 January, 2015)
- Poster session (22-24 January, 2015)
- Young Researchers Session (oral presentation - 24 January, 2015)
Marseille
and international exchange of ideas on implementing knowledge on
Local Organising Committee
Dr J. Ciccolini, Marseille, France
PAMM Scientific Committee
Pr G.J. Peters, Amsterdam, The Netherlands
optimizing cancer treatment. The conference will feature presentations from
internationally recognized leaders in the field of experimental, translational
and clinical oncology.
Scientists, researchers, and experts in the field of experimental
therapeutics will offer new insights and innovative approaches to treat
cancer, along with keynote lectures, oral and poster presentations.
Looking forward to meeting you all in Marseille in January 2015.
Local Organising Committee
Dr J. Ciccolini, Marseille, France
PAMM Scientific Committee
Pr G.J. Peters, Amsterdam, The Netherlands
Meeting Schedule
Wednesday, January 21 (p.m.): PAMM Investigational Drugs
& GPCO-Unicancer Business groups meetings (invitation only),
welcome reception
Thursday, January 22: Plenary Sessions, Poster Session & Football Match
Friday, January 23: Plenary Sessions, Poster Session & Social Event
Saturday, January 24 (a.m.): Young Researcher Session
Accommodation
Hôtel Novotel Marseille Vieux Port
36, boulevard Charles Livon, 13007 Marseille
tel: +33 (0)4 96 11 42 11
www.novotel.com
New Hotel of Marseille
71 Boulevard Charles Livon, 13007 Marseille
tel: +33 (0)4 91 31 53 15
www.new-hotel.com
Radisson Blu Hôtel
38-40, Quai de Rive Neuve, 13007 Marseille
tel: +33 (0)4 88 44 52 00 www.radissonblu.fr/hotel-marseille
Ibis Budget Vieux Port
46 rue Sainte, 13001 Marseille
tel: +33 (0)8 92 68 05 82
www.ibis.com
Venue
Amphithéâtre Marseille Provence Métropole
Les Jardins du Pharo, 58, Bd Charles Livon - 13007 Marseille - France
tel: +33 (0)4 95 09 59 00
www.marseille-provence.com
contact & registration
Etienne Jarry
12, Bd Fellen - 13016 Marseille - France
tel: +33 (0)4 91 09 70 53 [email protected]
www.comnco.com
PRELIMINARY PROGRAM
1. MODELING & SIMULATION IN ONCOLOGY
4. OMICS & IMAGING IN ONCOLOGY
Developing mathematical support in oncology is a rising trend both at the
bench and the bedside. This session will focus on the variety of models that can
be used today to better understand cancer biology and to improve anticancer
agents efficacy and clinical use, i.e., mechanistic and semi-mechanistic models,
PBPK approaches, computational driven regimen, new PK/PD modeling tools,
etc...
Translational oncology has benefited from recent advances in the field of in
vitro and in vivo imaging, plus the rise of -omics (e.g., metabolomics, proteomics,
etc..).This technical session will present the latest tools and applications made
available in experimental and translational oncology.
KEYWORDS:
Computational Oncology - Modeling & Simulation - PK/PD
Metronomics has been first introduced in paediatric oncology and is now also
considered as an attractive option in a variety of settings in adults. Beside the
reduction of drug-induced toxicities, novel mechanisms of action (i.e., antiangiogenic or immunostimulating properties) have emerged from the use of
low doses of anticancer drugs. This session will cover the achievements, current
limits and expectancies of metronomic chemotherapy in cancer.
Metronomics - Paediatrics Oncology - Drug Repositionning
3. BIOGUIDED ONCOLOGY
Biomarker-based medicine has been now widely integrated in clinical practice
in melanoma, colorectal, lung or breast cancers. Still, there is still a discrepancy
between the plethora of putative markers constantly published and the number
of validated tests actually reaching bedside applications. This session will
cover the latest tools made available to screen patients, the latest markers
emerging from molecular biology, and the latest clinical applications in
pharmacogenetics and pharmacogenomics.
KEYWORDS: Precision medicine - Pharmacogenetics - Pharmacogenomics
- Biomarker-based medicine
st
A. Larsen, Paris, FR
U. Ledzewicz, Edwardsville, USA
HL. Mc Leod, Tampa, USA
C. Meille, Basel, CH
G. Milano, Nice, FR
E. Pasquier, Randwick, AUS
GJ. Peters, Amsterdam, NL
JF. Seitz, Marseille, FR
JC. Soria, Villejuif, FR
C. Van Hasselt, Leiden,NL
M. Ychou, Montpellier, FR
W. Zamboni, Chapel Hill, USA
BY PHONE
BY FAX
BY MAIL
REGISTER ONLINE
Optimizing drug delivery of anticancer agents is an attractive strategy to optimize
the efficacy/toxicity balance. This session will cover the latest advances in the
field of medical chemistry applied to nanomedicine in oncology (i.e., conjugated
drugs, nanoparticles, smart drugs).
KEYWORDS:
Title: F
PROF
Com&Co SARL, 12 Bd Fellen, 13016 Marseille, France
+33 (0) 4 91 09 70 53
+33 (0) 4 96 15 33 08
[email protected]
www.pamm2015.com
F
DR
F
MR
F
MS
LAST NAME ............................................................................................................................................................................
FIRST NAME...........................................................................................................................................................................
INSTITUTION / COMPANY.................................................................................................................................................
Medicinal chemistry - Nanoparticles - Drug delivery
DEPARTMENT .......................................................................................................................................................................
6. BIOTECHNOLOGIES & IMMUNOTHERAPY
Clinical oncology has benefited over the last decade of the rise of novel
bioengineered entities.This session will cover the most recent advances beside
monoclonal antibodies (i.e., peptibodies, nanobodies and other entities) that are
now developed to adress novel targets, including to trigger immune response
against cancer.
KEYWORDS:
Biologics - Immunotherapy - Novel scafolds
ADDRESS ................................................................................................................................................................................
POST CODE ..............................CITY ....................................................................................................................................
COUNTRY ...............................................................................................................................................................................
PHONE ....................................................................................................................................................................................
E-MAIL ....................................................................................................................................................................
REGISTRATION FEES
7. WHAT’S IN THE PIPE?
BEFORE NOV 15
This session will present all the drugs currently in registration trials or recently
approved by experts in the field.
KEYWORDS:
CONFIRMED SPEAKERS (as of October the 1 , 2014)
N. André, Marseille, FR
F. André, Villejuif, FR
F. Barlési, Marseille, FR
JP. Benoit, Angers, FR
S. Benzekry, Bordeaux, FR
J. Bonner, Newcastle, UK
H. Calvert, London, UK
R. Costello, Marseille, FR
P. Couvreur, Paris, FR
M. D'Incalzi, Milano, IT
A. Di Paolo, Pisa, IT
D. Jodrell, Cambridge, UK
M. Joerger, St Gallen, CH
Metabolomics - Proteomics - Imaging - Experimental Therapeutics
5. NANOTECHNOLOGY & DRUG DELIVERY
2. METRONOMIC CHEMOTHERAPY
KEYWORDS:
KEYWORDS:
REGISTRATION FORM
RETURN TO
Next generation drugs - Clinical development
MAJOR SPONSORS
F
F
F
F
Non PAMM members
PAMM Members
Student
Social Event
200 €
150 €
50 €
50 €
F PAMM Indoor Football match
AFTER NOV 15
250 €
200 €
50 €
55 €
F Yes
F No
PAYMENT
F By credit card (Visa / Mastercard / no other card)
On protected payment Paybox online form, directly on the website www.comnco.com.
Please indicate your Name + PAMM 2015 in the part: «Additional details»
PARTNER
F By check enclosed (make check in euro payable in France to Com&Co)
F By bank transfer to Com&Co SARL
Bank Banque Chaix
41-43, Bd Peytral – 13006 Marseille, France
IBAN FR76 1017 8000 2600 2626 3880 380
BIC CCBPFRPPCHX